ResMed Inc. (RMD) CFO Brett Sandercock Sells 2,000 Shares
ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,000 shares of the stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $98.53, for a total value of $197,060.00. Following the sale, the chief financial officer now owns 73,072 shares of the company’s stock, valued at approximately $7,199,784.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Brett Sandercock also recently made the following trade(s):
- On Thursday, February 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The shares were sold at an average price of $93.42, for a total value of $186,840.00.
- On Thursday, February 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $100.13, for a total value of $125,162.50.
- On Tuesday, January 2nd, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $84.99, for a total value of $106,237.50.
ResMed Inc. (NYSE:RMD) opened at $97.75 on Tuesday. The stock has a market capitalization of $14,034.01, a price-to-earnings ratio of 48.88 and a beta of 0.94. ResMed Inc. has a 52 week low of $67.04 and a 52 week high of $104.78.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Thursday, February 8th were paid a $0.35 dividend. The ex-dividend date of this dividend was Wednesday, February 7th. This represents a $1.40 dividend on an annualized basis and a yield of 1.43%. ResMed’s dividend payout ratio (DPR) is 70.00%.
Several brokerages have recently commented on RMD. Zacks Investment Research lowered ResMed from a “buy” rating to a “hold” rating in a report on Monday, February 5th. Needham & Company LLC upgraded ResMed from an “underperform” rating to a “hold” rating in a report on Tuesday, January 23rd. Northland Securities upgraded ResMed from an “under perform” rating to a “market perform” rating in a report on Tuesday, January 23rd. ValuEngine upgraded ResMed from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, BMO Capital Markets increased their price objective on ResMed to $82.00 and gave the company a “market perform” rating in a report on Tuesday, December 12th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $75.17.
A number of hedge funds have recently modified their holdings of RMD. Cubist Systematic Strategies LLC purchased a new position in ResMed in the 3rd quarter worth $113,000. Calton & Associates Inc. purchased a new position in ResMed in the 4th quarter worth $115,000. Conning Inc. purchased a new position in ResMed in the 4th quarter worth $203,000. Commerzbank Aktiengesellschaft FI purchased a new position in shares of ResMed during the 4th quarter valued at about $206,000. Finally, Dowling & Yahnke LLC purchased a new position in shares of ResMed during the 4th quarter valued at about $208,000. Institutional investors own 62.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/03/20/resmed-inc-rmd-cfo-brett-sandercock-sells-2000-shares.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.